このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Axonics 将来の成長

Future 基準チェック /46

Axonics利益と収益がそれぞれ年間54.3%と16.4%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に3.9% 54.4%なると予測されています。

主要情報

54.3%

収益成長率

54.4%

EPS成長率

Medical Equipment 収益成長	16.7%
収益成長率	16.4%
将来の株主資本利益率	3.9%
アナリストカバレッジ	Good
最終更新日	28 May 2024

今後の成長に関する最新情報

Recent updates

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Jul 14

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Jun 20

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Mar 27

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Feb 28

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

May 30

Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

Apr 19

We're Hopeful That Axonics (NASDAQ:AXNX) Will Use Its Cash Wisely

Sep 15

業績と収益の成長予測

NasdaqGS:AXNX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	632	56	N/A	N/A	7
12/31/2025	537	36	94	N/A	12
12/31/2024	447	-2	53	N/A	13
3/31/2024	387	-16	-16	-10	N/A
12/31/2023	366	-6	-6	-2	N/A
9/30/2023	343	-12	-1	2	N/A
6/30/2023	320	-32	-9	-7	N/A
3/31/2023	296	-46	9	12	N/A
12/31/2022	274	-60	1	3	N/A
9/30/2022	241	-76	-16	-13	N/A
6/30/2022	217	-77	-22	-20	N/A
3/31/2022	194	-80	-33	-31	N/A
12/31/2021	180	-80	-50	-47	N/A
9/30/2021	162	-76	-71	-69	N/A
6/30/2021	150	-68	-87	-85	N/A
3/31/2021	120	-63	-88	-86	N/A
12/31/2020	112	-55	-87	-84	N/A
9/30/2020	87	-66	-86	-84	N/A
6/30/2020	53	-82	-90	-88	N/A
3/31/2020	39	-81	-95	-94	N/A
12/31/2019	14	-80	-85	-83	N/A
9/30/2019	4	-67	-66	-65	N/A
6/30/2019	3	-49	-50	-49	N/A
3/31/2019	2	-39	-39	-38	N/A
12/31/2018	1	-32	-33	-31	N/A
9/30/2018	0	-28	-29	-27	N/A
6/30/2018	0	-25	-25	-24	N/A
3/31/2018	0	-20	-22	-21	N/A
12/31/2017	0	-18	N/A	-18	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AXNXは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: AXNX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: AXNX今後 3 年以内に収益を上げることが予想されます。

収益対市場: AXNXの収益 ( 16.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: AXNXの収益 ( 16.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AXNXの自己資本利益率は、3年後には低くなると予測されています ( 3.9 %)。

Axonics 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Forecast breakeven date pushed back to 2025

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Forecast breakeven date moved forward to 2024

Axonics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Consensus estimates of losses per share improve by 37%

Axonics, Inc. Provides Revenue Guidance for 2023

Recent updates

Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia

Forecast breakeven date pushed back to 2025

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

Medtronic Files Itc Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations

Full year 2023 earnings: EPS exceeds analyst expectations

Chief Commercial Officer exercised options and sold US$1.1m worth of stock

Insufficient new directors

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.

Chief Medical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Axonics, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Axonics, Inc. Announces Chief Financial Officer Changes

Chief Commercial Officer notifies of intention to sell stock

Forecast breakeven date moved forward to 2024

Axonics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Consensus estimates of losses per share improve by 37%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

President & CFO notifies of intention to sell stock

Now 20% undervalued after recent price drop

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS exceeds analyst expectations

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Chief Operating Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

Executive VP exercised options and sold US$705k worth of stock

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Chief Commercial Officer exercised options and sold US$1.9m worth of stock

Axonics, Inc. Provides Revenue Guidance for 2023

Forecast to breakeven in 2025

Axonics, Inc. to Report Fiscal Year 2022 Results on Jan 11, 2023

Independent Director recently sold US$135k worth of stock

Axonics, Inc. Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Year 2022

Axonics, Inc. to Report Q3, 2022 Results on Oct 31, 2022

Axonics stock falls 5.6% after Needham downgrades rating

Chief Technology Officer notifies of intention to sell stock

Executive VP exercised options and sold US$551k worth of stock

Chief Medical Officer recently sold US$748k worth of stock

Axonics Announces First Patient Implants in Canada with New Recharge-Free Sacral Neuromodulation System

Axonics Stock Is A Buy Amid Current Capex Cycle

Executive VP notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Consensus estimates of losses per share improve by 13%

Axonics prices stock offering of 1.75M shares

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth

Axonics, Inc. Updates Revenue Guidance for the Year of 2022

Axonics, Inc. to Report Q2, 2022 Results on Aug 01, 2022

Independent Director notifies of intention to sell stock

Axonics, Inc. Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2022

Axonics, Inc. Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System

Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

Axonics, Inc., Annual General Meeting, May 25, 2022

Axonics, Inc. to Report Q1, 2022 Results on May 05, 2022

Independent Director notifies of intention to sell stock